Removing Prions that Cause Mad Cow in Humans from Blood - Pall Technology Featured at FDA Advisory Meeting

Business Wire, Feb 8, 2005

Management uses certain non-GAAP measurements to assess Pall's current and future financial performance. The non-GAAP measurements do not replace the presentation of Pall's GAAP financial results. These measurements provide supplemental information to assist management in analyzing Pall's financial position and results of operations. Pall has chosen to provide this information to facilitate meaningful comparisons of past, present and future operating results and as a means to emphasize the results of ongoing operations.

Editor's Note:

--Dr. Coker's FDA TSE Advisory Committee presentation along with photos and additional information on prions and The Leukotrap Affinity Prion Reduction Filter can be found at www.pall.com/corporate_35354.asp

--Interviews with Pall scientists and executives are available upon request.